Structural MRI: We will examine migraine and epilepsy patients as well as healthy controls using conventional structural MRI in the brain and spinal cord including T1-, T2-, and T2\*-weighted sequences
Quantitative MRI: We will examine migraine and epilepsy patients as well as healthy controls using quantitative MRI in the brain and spinal cord. This includes multi-parameter mapping (MPM) and quantitative susceptibility mapping (QSM).
Diffusion MRI: We will examine migraine and epilepsy patients as well as healthy controls using diffusion MRI in both brain and spinal cord.
fMRI: We will examine migraine and epilepsy patients as well as healthy controls using resting-state and task fMRI (including sensory stimulation using pain stimulus) in both brain and spinal cord.
MR Spectroscopy: We will examine migraine and epilepsy patients as well as healthy controls using MR Spectroscopy in both brain and spinal cord.
Study summary
In this project, the aim is to recruit patients with drug resistant epilepsy and those suffering from migraine. Interestingly, patients suffering from epilepsy are also more often reporting to suffer from migraine. The pathobiology is understudied, but it is believed that both etiologies results from brain networks changes. A clinical certified 7T Terra Siemens scanner will be employed to assess in all participants (including healthy controls) how the microstructure differs in disease specific areas. Patients will further be clinically assessed as well as undergo questionnaires.
Migraine is also a common comorbidity to visual snow syndrom and has been shown to impact similar brain regions. However, the pathophysiology is still understudied and a better understanding of the two diseases is needed.
Eligibility
Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
Accepted
Inclusion Criteria:
Patients:
* Patient must be able to read and sign the informed consent form
* Stable prophylactic medication for 2 months prior to MRI
* At leat one of the two criteria applies:
* Patients diagnosed with migraine (with or without aura, episodic or chronic). Diagnosis is ensured by clinical interview (at least 8 weeks prior to MRI). Also, patients complete a migraine questionnaire (HARDSHIP) (at least 8 weeks before MRI). Migraine frequency ≥ 2 migraine attacks/month.
* Patients with drug resistent epilepsy accroding to ILAE crtieria
* Patients with diagnoses of Visual snow syndrome
Healthy participants;
* No migraine (validated by questionnaire) or epilepsy
* Participants must be able to read and sign the informed consent form
Exclusion Criteria:
* Treatment of migraine disease with Botox within \< 4 months before baseline and during the study period
* Pregnant or breastfeeding women
* Intention during the course of the trial to become pregnant
* Women with bilateral ovariectomy, with or without hysterectomy, and postmenopausal women (\>2 years of age) are not considered childbearing.
* Other clinically significant comorbidities (e.g., renal insufficiency, hepatic dysfunction, cardiovascular disease, etc.),
* Known or suspected noncompliance with the protocol, drug or alcohol abuse,
* Patient's inability to follow trial procedures, e.g., due to language problems, mental illness, dementia, etc.,
* Prior participation in the clinical trial
* Enrolment of the investigator, his/ her family members, employees and other dependent persons of the test personnel
* Metallic objects in the body (e.g., splinters, MR incompatible implants).
* Pacemaker
* Claustrophobia
* Obesity (body mass index \> 35 kg/m2)
Primary outcome measure(s)
MR: multi-parameter mapping (MPM) — Once during visit 2 (1-2 weeks after visit 1)
MR: quantitative susceptibility mapping (QSM) — Once during visit 2 (1-2 weeks after visit 1)
Resting-state fMRI (brain and brainstem/spinal cord) — Once during visit 2 (1-2 weeks after visit 1)
MR: whole-brain structural scans — Once during visit 2 (1-2 weeks after visit 1)
MR: routine clinical scans — Once during visit 2 (1-2 weeks after visit 1)
MR spectrosocpy — Once during visit 2 (1-2 weeks after visit 1)
MR: diffusion imaging — Once during visit 2 (1-2 weeks after visit 1)
MR: axial T2*w sequence — Once during visit 2 (1-2 weeks after visit 1)
Task-fMRI — Once during visit 2 (1-2 weeks after visit 1)
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.